YT-M95 YT-M95 Shenzhen Sunshine Technology Co.,Ltd , https://www.yatwinsz.com
Guangdong doctor team found PD-1 immunotherapy effective treatment of nasopharyngeal carcinoma
Medical Network September 13th Nasopharyngeal cancer is also known as "Guangdong cancer", the incidence of nasopharyngeal cancer in Guangdong Province is more than five times the average incidence rate in mainland China. Sun Yat-sen University Cancer Hospital said on the 12th that the Department of Internal Medicine, the tension team of the hospital found that "PD-1 monoclonal antibody (carbelizumab) single drug and combined gemcitabine + cisplatin" regimen has good safety for nasopharyngeal carcinoma and Efficacy.
The relevant research results were published in "Lancet Oncology" on September 11th, Beijing time.
According to the Guangdong Provincial Center for Disease Control and Prevention official website shows, according to World Health Organization estimates that NPC cases worldwide of about 80% in China. According to the latest data from the Guangdong Provincial Cancer Registry (2009), the incidence of nasopharyngeal cancer in Guangdong Province is more than five times the national average.
Advanced nasopharyngeal carcinoma has been treated with chemotherapy for a long time, lacking high-efficiency, low-toxic targeted drugs and new treatments.
At this stage, the main research direction of immunotherapy in the world is immunological checkpoint inhibitors, including PD-1/PD-L1 inhibitors. PD-1 inhibitors can reactivate the tumor recognition function of T cells and eliminate them, giving patients hope for long-term survival.
In order to find a better, more effective and less toxic treatment plan, the tension team started two phase I clinical studies in 2016 to study the recurrence of PD-1 monoclonal antibody (careliuzumab) after first-line treatment failure. Patients with nasopharyngeal carcinoma were treated with cisplatin plus gemcitabine regimen in combination with the new PD-1 monoclonal antibody (carelibizumab).
The results showed that in the monotherapy group, the overall overall effective rate was 34%, and the disease control rate was 59%. In the combined treatment group, the overall effective rate was 91%, the disease control rate was as high as 100%, and the toxicity of the combined chemotherapy group was chemotherapy. Mainly toxic, basically controllable.
Fang Wenfeng, deputy director of the Cancer Hospital of Sun Yat-sen University, said that the PD-1 inhibitor carelibizumab showed low toxicity and high efficiency in the treatment of nasopharyngeal carcinoma, which may improve the survival and quality of life of patients with advanced nasopharyngeal carcinoma. , immunotherapy will change the treatment mode of nasopharyngeal cancer.
The team is conducting two registered clinical studies on advanced immunotherapy for nasopharyngeal carcinoma, which is expected to be approved by the State Food and Drug Administration in the past two years, including a single-drug treatment with carelitozumab after second-line treatment of advanced nasopharyngeal carcinoma. Register for a clinical study. (Finish)